Research Article
Egg and cholesterol consumption and mortality from cardiovascular and different causes in the United States: A population-based cohort study
Pan Zhuang, Roles Formal analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing
Affiliations National Engineering Laboratory of Intelligent Food Technology and Equipment, Fuli Institute of Food Science, Zhejiang University, Hangzhou, Zhejiang, China, Key Laboratory for Agro-Products Postharvest Handling of Ministry of Agriculture and Rural Affairs, Zhejiang Key Laboratory for Agro-Food Processing, Zhejiang University, Hangzhou, Zhejiang, China, Department of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou, Zhejiang, China ⨯
Fei Wu, Roles
Reply
James K. Aikins, Jr., MD, FACOG, FACS
New Brunswick, February 4, 2021 – Expanding its team of highly specialized professionals in the treatment of routine, rare and complex cancers of the female reproductive system, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH), a RWJBarnabas Health facility, have named James K. Aikins, Jr., MD, FACOG, FACS chief of gynecologic oncology at Rutgers Cancer Institute and chief of gynecologic oncology services at RWJUH, New Jersey s largest academic medical center. He will also serve as Program Director for the Gynecologic Oncology Fellowship Program at Rutgers Robert Wood Johnson Medical School.
Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment
Research by Rutgers Cancer Institute of New Jersey and RWJBarnabas Health researcher and international collaborators can help identify prognosis and stratify risk
News provided by
Share this article
(PRNewsfoto/Rutgers Cancer Institute of New Jersey and RWJBarnabas Health)
NEW BRUNSWICK, N.J., Jan. 28, 2021 /PRNewswire/ Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. The research from the Burkitt Lymphoma International Prognostic Index Consortium is published in the January 2021 online issue of
E-Mail
Credit: University of Cincinnati
PORTLAND, OR - A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in
JAMA Oncology.
While the trial findings did not show a direct patient benefit, they do show that it s possible to safely administer chemotherapy prior to pancreatic cancer surgery. They also pave the way for better treatment testing for this notorious killer. With no symptoms in the early stages, and few effective therapies, pancreatic cancer is the fourth-most deadly cancer type in the United States. According to the American Cancer Society, only 20 percent of pancreatic cancer patients are alive one year after diagnosis. After five years, only about 7 percent are alive.